HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

6-Aminocaproic Acid (6 Aminocaproic Acid)

Subscribe to New Research on 6-Aminocaproic Acid

An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

Also Known As:

6 Aminocaproic Acid; Amicar; CY-116; Caprocid; Epsamon; Epsikapron; 6 Aminohexanoic Acid; Acid, 6-Aminocaproic; Acid, 6-Aminohexanoic; Acid, epsilon-Aminocaproic; CY 116; CY116; epsilon Aminocaproic Acid; 6-Aminohexanoic Acid; epsilon-Aminocaproic Acid; Hexanoic acid, 6-amino-

Networked: 422 relevant articles (31 outcomes, 40 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Thompson, George H: 5 articles (11/2008 - 02/2004)
2.	Florentino-Pineda, Ivan: 5 articles (11/2008 - 02/2004)
3.	Poe-Kochert, Connie: 5 articles (11/2008 - 02/2004)
4.	Sieckman, Gary L: 3 articles (04/2014 - 10/2010)
5.	Hoffman, Timothy J: 3 articles (04/2014 - 10/2010)
6.	Smith, Charles J: 3 articles (04/2014 - 10/2010)
7.	Rold, Tammy L: 3 articles (04/2014 - 10/2010)
8.	Armstrong, Douglas G: 3 articles (11/2008 - 02/2007)
9.	Errico, Thomas: 2 articles (04/2015 - 05/2014)
10.	Verma, Kushagra: 2 articles (04/2015 - 05/2014)

Related Diseases

1.	Hemorrhage 08/01/1995 - "Previous studies indicate a significant reduction of intraoperative and postoperative bleeding in patients receiving Amicar during open heart surgery. " 03/01/1990 - "The use of small doses of epsilon aminocaproic acid was not accompanied by significant complications and appeared to be effective in special situations for the control of urinary bleeding. " 03/16/1974 - "Treatment with epsilon aminocaproic acid was associated with rapid and permanent cessation of bleeding, gradual improvement in renal function, and disappearance of the renal artery bruit. " 03/01/1990 - "Safe and effective, prolonged administration of epsilon aminocaproic acid in bleeding from the urinary tract." 01/01/2015 - "The efficacy of epsilon aminocaproic acid (EACA) as a prophylactic treatment for postoperative bleeding after pediatric open-heart surgery has not been determined. "
2.	Scoliosis 11/15/2008 - "Amicar was highly effective in decreasing perioperative blood loss and transfusion requirements in patients with neuromuscular scoliosis undergoing PSF and SSI. " 09/15/2008 - "Amicar was highly effective in decreasing total perioperative blood loss and transfusion requirements in same-day ASF and PSF with SSI for idiopathic scoliosis. " 05/15/2001 - "A prospective study evaluating the efficacy of epsilon-aminocaproic acid (EACA) in decreasing perioperative blood loss in idiopathic scoliosis. " 09/01/2005 - "Four separate studies on the role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. " 11/15/2008 - "Role of Amicar in surgery for neuromuscular scoliosis."
3.	Postoperative Hemorrhage 02/01/2000 - "We have studied the efficacy of epsilon aminocaproic acid in reducing postoperative blood loss in infants and children with congenital cyanotic cardiac anomalies undergoing corrective operative procedures. " 02/01/2000 - "Epsilon aminocaproic acid in paediatric cardiac surgery to reduce postoperative blood loss." 06/01/2002 - "To determine if the use of an antifibrinolytic agent (epsilon aminocaproic acid [EACA]) decreased perioperative and postoperative blood loss in patients who underwent total hip arthroplasty (THA). " 11/01/1963 - "[THERAPY OF POSTOPERATIVE HEMORRHAGE FOLLOWING PROSTATECTOMY WITH SPECIAL REFERENCE TO THE EFFECT OF 6-AMINOCAPROIC ACID]." 02/01/2000 - "It was found that epsilon aminocaproic acid is effective in reducing postoperative blood loss, packed red cells and plasma product requirements in paediatric patients undergoing corrective surgical procedures for congenital cyanotic heart diseases."
4.	Heart Diseases (Heart Disease) 06/06/1970 - "Epsilon-aminocaproic acid in preoperative correction of haemostatic defect in cyanotic congenital heart-disease." 02/01/2000 - "It was found that epsilon aminocaproic acid is effective in reducing postoperative blood loss, packed red cells and plasma product requirements in paediatric patients undergoing corrective surgical procedures for congenital cyanotic heart diseases." 06/01/1974 - "The use of epsilon-aminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease." 10/01/2000 - "Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease." 10/01/2000 - "Epsilon aminocaproic acid is as efficacious as low dose aprotinin in reducing postoperative blood loss and packed red blood cell and platelet requirements in children with congenital cyanotic heart disease. "
5.	Wounds and Injuries (Trauma) 05/01/1975 - "Epsilon-aminocaproic acid (EACA) was intravenously administered to rabbits subjected to bilateral renal crushing trauma. " 10/28/1972 - "Epsilon-aminocaproic acid in the treatment of renal trauma." 11/01/1966 - "The effect of epsilon aminocaproic acid on the healing of extraction wounds in hamsters." 01/01/1977 - "The efficacy of antifibrinolytic therapy with epsilon aminocaproic acid (EACA) in experimental spinal cord injury is assessed by use of a standardized trauma model at both nonparaplegic and paraplegic trauma doses. " 10/01/1987 - "Forty-nine patients, ages 3 to 18 years, who sustained nonpenetrating unilateral trauma with hyphemas were assigned randomly to receive either 100 mg/kg of epsilon-aminocaproic acid (EACA), an antifibrinolytic agent, orally every 4 hours for 5 days (maximum 30 g/day) or a placebo. "

Related Drugs and Biologics

1.	Tranexamic Acid (AMCA)
2.	Aprotinin (Trasylol)
3.	Fibrinogen (Factor I)
4.	6-Aminocaproic Acid (6 Aminocaproic Acid)
5.	Heparin (Liquaemin)
6.	Deamino Arginine Vasopressin (Desmopressin)
7.	Lysine (L-Lysine)
8.	Serine Proteases (Serine Protease)
9.	Factor IX (PTC)
10.	Dacarbazine (DIC)

Related Therapies and Procedures

1.	Spinal Fusion (Spondylosyndesis)
2.	Cardiopulmonary Bypass (Heart-Lung Bypass)
3.	Arthrodesis
4.	Myocardial Revascularization
5.	Extracorporeal Circulation